This executive summary examines how consumer demand for mobility and active aging is reshaping the joint health supplement category, and how MyCondro™, a fermentation-derived, non-animal chondroitin sulfate, addresses challenges with raw material variability, traceability, and sustainability. It reviews the role of chondroitin sulfate in cartilage biology, pharmacokinetic data showing greater plasma concentration than animal-derived chondroitin, and two randomized, placebo-controlled trials conducted at 600 mg daily. It also outlines practical formulation and brand positioning considerations for product developers.
The proposal would reverse FDA’s position that N-acetyl-L-cysteine is excluded from the supplement definition and would replace the agency’s enforcement discretion policy if finalized.
The effort targets adulteration, inconsistent quality documentation, and trade barriers, with a pilot that tests a shared quality protocol on real ingredient materials.
Forty-eight percent of respondents prioritized advice from qualified experts as a trust signal, while 50% trust AI tools, and 39% trust influencers for wellness advice.
Todd Harrison of Venable LLP says AB 2779 rightly removes supplements out of California’s food date rules, but brands still need stability data, contract manufacturer oversight, and federal uniformity.